Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Relmada Therapeutics Inc (RLMD) PT Raised to $90 at Truist Securities
July 27, 2021 10:14 AM EDTTruist Securities analyst Joon Lee raised the price target on Relmada Therapeutics Inc (NASDAQ: RLMD) to $90.00 (from $75.00) while maintaining a Buy rating.
... MoreRelmada Therapeutics (RLMD) to Resume Trading at 8:30 a.m.
July 27, 2021 8:26 AM EDTRelmada Therapeutics (NASDAQ: RLMD) to Resume Trading at 8:30 a.m.
Relmada Therapeutics (RLMD) Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
July 27, 2021 7:35 AM EDTRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3... More
Relmada Therapeutics (RLMD) Halted, News Pending
July 27, 2021 7:25 AM EDTRelmada Therapeutics (NASDAQ: RLMD) Halted, News Pending
